Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With "Risk-organ" Multi-system Langerhans Cell Histiocytosis

被引:13
|
作者
Luis Braier, Jorge [1 ]
Rosso, Diego [1 ]
Latella, Antonio [2 ]
Chantada, Guillermo [1 ]
Ozuna, Blanca [3 ]
Ripoli, Mario [4 ]
Scopinaro, Marcelo [1 ]
机构
[1] Hosp Nacl Pediat Juan P Garrahan, Dept Hematol Oncol, RA-1245 Buenos Aires, DF, Argentina
[2] Hosp Nacl Pediat Juan P Garrahan, Dept Pediat, RA-1245 Buenos Aires, DF, Argentina
[3] Hosp Nacl Pediat Juan P Garrahan, Dept Nutr, RA-1245 Buenos Aires, DF, Argentina
[4] Univ Buenos Aires, Dept Pediat, Buenos Aires, DF, Argentina
关键词
anemia; thrombocytopenia with or without leukopenia; hypoalbuminemia; prognosis; Langerhans cell histiocytosis; RANDOMIZED TRIAL; CHILDREN; DISEASE; ALPHA;
D O I
10.1097/MPH.0b013e3181d7acc5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To perform a risk factor analysis in patients with "risk organ" multi-system Langerhans cell histiocytosis at diagnosis. Methods: From 1987 to 2007, 77 patients were analyzed. A univariate analysis of the variables, age <2 years, lungs, spleen and hepatic involvement, presence of >2 risk involved organs, hypoalbuminemia and the presence of isolated anemia, anemia with thrombocytopenia with or without leukopenia at diagnosis was performed. Statistically significant variables were combined and entered into a multivariate analysis. Results: Fifty-six and 66 evaluable patients had hematologic and hepatic involvement at diagnosis, respectively. Among the hematologic patients, the subgroup of anemia with thrombocytopenia with or without leukopenia showed a significantly lower 5-year survival than the subgroup of isolated anemia (0.19 vs. 0.87, respectively; P = 0.0001). Of all the patients, those with hypoalbuminemia had a 5-year survival of 0.16 compared with those with normal albumin levels, who had a 5-year survival of 0.65 (P < 0.0001). In multivariate analysis, only anemia with thrombocytopenia with or without leukopenia and hypoalbuminemia were the independent risk factors (relative risk 3.77; confidence interval, 1.7-8.4; P < 0.0011 and relative risk 2.59; confidence interval, 1.24-5.4; P < 0.0112). Conclusions: Anemia with thrombocytopenia with or without leukopenia and hypoalbuminemia, were associated with worse prognosis in multi-system Langerhans cell histiocytosis. Other therapeutic strategies should be considered at diagnosis or early during the initial treatment for this high risk subgroup of patients.
引用
收藏
页码:E122 / E125
页数:4
相关论文
共 47 条
  • [21] Biomodulatory Metronomic Therapy Shows Remarkable Activity in Chemorefractory Multi-System Langerhans Cell Histiocytosis
    Heudobler, Daniel
    Rehe, Klaus
    Foell, Juergen
    Corbacioglu, Selim
    Hildebrandt, Gerhard
    Herr, Wolfgang
    Reichle, Albrecht
    Vogelhuber, Martin
    BLOOD, 2016, 128 (22)
  • [22] DEVELOPMENT OF RHEUMATOID ARTHRITIS DURING THE LONG TIME COURSE OF MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS
    Tiganova, Olga
    Bronin, Gleb
    Kondratchik, Konstantin
    Kovaliova, Olga
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 691 - 691
  • [23] Vaccine Associated Soft Tissue Infiltrate Can Predispose Multi-System Langerhans Cell Histiocytosis
    Bronin, Gleb
    Kislyakov, Alexey
    Kondratchik, Konstantin
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S2 - S2
  • [24] Relapses in Pediatric Patients with Multi-System or Multi-Focal bone Langerhans cell Histiocytosis - data from the Jlsg 96/02 study
    Sakamoto, Kenichi
    Morimoto, Akira
    Shioda, Yoko
    Imamura, Toshihiko
    Imashuku, Shinsaku
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S21 - S22
  • [25] Biomodulatory therapy induces long-lasting remissions in chemorefractory multi-system Langerhans cell histiocytosis
    Harrer, D. C.
    Jakob, M.
    Vogelhuber, M.
    Lueke, F.
    Rehe, K.
    Corbacioglu, S.
    Herr, W.
    Reichle, A.
    Heudobler, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 183 - 183
  • [26] MAPPING NON-BRAFV600E HEMATOPOIETIC CLONES IN MULTI-SYSTEM LANGERHANS CELL HISTIOCYTOSIS
    Milne, Paul
    Abhyankar, Harshal
    Scull, Brooks
    Singh, Preeti
    Chakraborty, Rikhia
    Collin, Matthew
    Allen, Carl E.
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [27] Bortezomib alone or in combinination with Doxil is active in adult refractory multi-system Langerhans cell histiocytosis (LCH)
    Haddad, Philip A.
    BLOOD, 2007, 110 (11) : 27B - 27B
  • [28] Activity of Bortezomib alone or in combination with Doxil in adult refractory multi-system Langerhans cell histiocytosis (LCH)
    Haddad, Philip A.
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 869 - 869
  • [29] Successful Vemurafenib Re-Challenge at Disease Reactivation in Refractory Multi-System Langerhans Cell Histiocytosis
    Soh, S. Y.
    Htet, L. L.
    Lian, D.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S403 - S404
  • [30] Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis
    Rao Nanduri, Vasanta
    Pritchard, Jon
    Levitt, Gill
    Glaser, Adam W.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) : 2563 - 2569